The efficacy of different dosages of oxaliplatin plus S-1 on thrombocytopenia for the treatment of advanced gastric cancer

doi:10.3877/cma.j.issn.2095-3224.2017.01.008

Abstract

Abstract:

Objective

To study the efficacy of different dosages of oxaliplatin plus S-1 on thrombocytopenia for the treatment of advanced gastric cancer.

Methods

Between August 2014 and May 2016, a total of 60 advanced gastric cancer patients at the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College were recruited to the study, and divided into two groups. Arm A received oxaliplatin at a dose of 100 mg/m² and arm B receiving oxaliplatin at a dose of 130 mg/m², started with SOX therapy. Adverse events were graded according to the National Cancer Institute-Common Toxicity Criteria version 3.0. This study used SPSS 19.0 software to undertake statistical analysis. Comparison of groups was statistically analyzed with X² test. Two-sided P<0.05 was used to indicate a statistically significant difference.

Results

In total, the most common grade 3/4 toxicities were anemia, leukopenia, neutropenia, thrombocytopenia, nausea and vomiting in the treatment of SOX therapy for advanced gastric cancer. The incidence ofgrade 3/4 thrombocytopenia in arm A was 6.67%, which was significantly lower in arm B with 30.0%. Grade 3/4 thrombocytopenia was significantly associated with the dose of oxaliplatin [OR=3.846, 95%CI (1.091~13.56), P=0.0286) ].

Conclusions

The dose of oxaliplatin was one of the factors which affected affects grade 3/4 thrombocytopenia in the treatment of SOX therapy for advanced gastric cancer patients.

Key words: Gastric neoplasms, Therapy, Thrombocytopenia, Oxaliplatin

Tao Qu, Lin Yang, Honggang Zhang, Chengxu Cui. The efficacy of different dosages of oxaliplatin plus S-1 on thrombocytopenia for the treatment of advanced gastric cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2017, 06(01): 37-40.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2017.01.008

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2017/V06/I01/37

Figures/Tables 2

References 10

[1]	Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA: a cancer journal for clinicians [J]. 2011, 61(2): 69-90.
[2]	孙秀娣，牧人，周有尚, 等. 中国胃癌死亡率20年变化情况分析及其发展趋势预测 [J]. 中华肿瘤杂志, 2004, 26(1): 4-9.
[3]	Cunningham D, Okines AF, Ashley S.Capecitabine and oxaliplatin for advanced esophagogastriccancer [J]. The New England journal of medicine, 2010, 362(9): 858-859.
[4]	Kang YK, Kang WK, Shin DB, et al.Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial [J]. Annals of oncology : official journal of the European Society for Medical Oncology/ESMO, 2009, 20(4): 666-673.
[5]	Wilson H, Lehky T, Thcmas RR, et al. Acute oxaliplatin-inducedperipheral nerve hyperexcitability [J]. J Clin Oncol, 2002, 20(7): 1767-1774.
[6]	Cunningham, D. MD, Rao S., Starling N., et al. Randomisedmulticentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patien TYMS with advanced oesophagogastric (OG) cancer: The REAL 2 trial [J]. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: LBA4017.
[7]	Koizumi W, Takiuchi H, Yamada Y., et al.Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study) [J]. Annals of oncology, 21(5): 1001-1005.
[8]	Hildebrandt MA, Gu J, Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC [J]. Expert Opin Drug Metab Toxicol, 2009, 5(7): 745-755.
[9]	Stoehlmacher J, Ghaderi V, Iobal S, et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer [J]. Anticancer Res, 2001, 21(4B): 3075-3079.
[10]	Park CJ, Choi BS. The Protein shuffle. Sequential interactions among components of the human nucleotide excision repair pathway [J]. FEBS J, 2006, 273(8): 1600-1608.

分组	例数	3/4度血小板减少症	非3/4度血小板减少症
A组	30	2（6.67）	28（93.3）
B组	30	9（30.0）	21（70.0）
X²值	4.007
P值	0.045

分组	例数	3/4度血小板减少症	非3/4度血小板减少症
A组	30	2（6.67）	28（93.3）
B组	30	9（30.0）	21（70.0）
X²值	4.007
P值	0.045

影响因素		单因素分析
影响因素		OR（95%CI）	P值
年龄		2.786（0.8291~9.3600）	0.0894
?	<55	?	?
?	≥55	?	?
性别		0.4286（0.0878~2.0930）	0.2842
?	男	?	?
?	女	?	?
TNM分期		0.3056（0.0636~1.4670）	0.1222
?	III	?	?
?	IV	?	?
手术类型		0.5208（0.1052~2.5780）	0.4177
?	全胃	?	?
?	部分胃	?	?
ECOG评分		0.8438（0.1626~4.3800）	0.8396
?	0	?	?
?	1	?	?
血小板减少症		3.846（1.0910~13.5600）	0.0286
?	100 mg/m²	?	?
?	130 mg/m²	?	?

影响因素		单因素分析
影响因素		OR（95%CI）	P值
年龄		2.786（0.8291~9.3600）	0.0894
?	<55	?	?
?	≥55	?	?
性别		0.4286（0.0878~2.0930）	0.2842
?	男	?	?
?	女	?	?
TNM分期		0.3056（0.0636~1.4670）	0.1222
?	III	?	?
?	IV	?	?
手术类型		0.5208（0.1052~2.5780）	0.4177
?	全胃	?	?
?	部分胃	?	?
ECOG评分		0.8438（0.1626~4.3800）	0.8396
?	0	?	?
?	1	?	?
血小板减少症		3.846（1.0910~13.5600）	0.0286
?	100 mg/m²	?	?
?	130 mg/m²	?	?

[1]	Xiaoli Yi, Shasha Hu, Yan Zhang. Impact of HER-2 low expression on response of neoadjuvant chemotherapy and prognosis in breast cancer patients [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 340-346.
[2]	Jie Shi, Yuntao Li, Haiyan Gao. Prognosis of node-positive luminal A breast cancer patients with neoadjuvant and adjuvant chemotherapy and influencing factors [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 353-361.
[3]	The Joint Surgery Branch of the Chinese Orthopedic Association, Guangdong’s Medical Association of Osteoporosis And Bone Mineral Research, Foshan Shunde 3rd Peoele’s Hospital. Clinical intervention guideline for using of anti-osteoporosis drugs in postoperative fragile hip fractures in China (2023 Edition) [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 751-764.
[4]	Zeying Jiang, Anting Wang, Jiaoli Wang, Ci Chen, Qiuling Zhou, Yanjuan Huang, Fang Zhou, Yan Xue, Jianfeng Zhou, Wenyong Tan, Meifang Du. Effect of multiple plant oils combination in preventing the chemoradiotherapy induced toxicities [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2023, 18(06): 523-527.
[5]	Wei Zhang. Dentoalveolar surgery: The pioneer of comfortable treatment [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2023, 17(06): 386-388.
[6]	Yuezhou Li, Kongxi Zhang, Xiaohong Li, Zhonghua Shang. Prognostic significance of PUM in gastric carcinoma based on bioinformatics analysis [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 426-432.
[7]	Jun Zhang, Zai Luo, Mingyu Duan, Zhengjun Qiu, Chen Huang. Research progress of prognostic prediction models for gastric cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 456-461.
[8]	Dechen Wang, Kang Yang, Zijie Yang, Mingbin Gui, Lianping Qu, Xiaofeng Zhang, Feng Gao. Progress of microsatellite stability state and PD-1/PD-L1/IDO in colorectal carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 462-465.
[9]	Yanhui Zhang, Jiao Zhang, Zhixian Zhu. Effect of indwelling anal tube on anastomotic leakage after laparoscopic total mesangectomy after neoadjuvant chemoradiotherapy in patients with middle and low rectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 25-28.
[10]	Bo Kong, Jing Zhang, Ke Lyu. Review on the role of ultrasonography in the diagnosis and treatment of complex ventral hernia [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2023, 17(06): 670-673.
[11]	Xiaoyong Wei. Discussion on the focus issues of conversion therapy for primary liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 602-607.
[12]	Huiying Ma, Xinling Fan, Shirui Tan, Jiayun Chen, Ying Cao, Yuan Xu, Jing Jin, Yuan Tang. Magnetic resonance linac for locally advanced rectal cancer: a preliminary experience [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 519-523.
[13]	Ruixue Yue, Lingxin Kong, Xin Hao, Jinqiang Yang, Meng Han, Guozhong Cui, Jianjun Wang, Zhisheng Zhang, Fanting Kong, Wei Zhang, Wenbo He, Xianqiao Li, Xinping Zhou, Donghong Xu, Chongzhu Hu. HER2 protein expression levels predict efficacy of neoadjuvant therapy in breast cancer: A real-world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 765-770.
[14]	Yingqian Li, Huashan Li. Evaluation of treatment methods for complete rectal prolapse: a real world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 700-705.
[15]	Meisha Fu, Yuhua Zhou, Hui Li, Chunyan Xue. Effect of lymphocyte immunotherapy on T lymphocyte subset distribution and PD1/PD-L1 expression in patients with recurrent miscarriage [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 726-730.

Please choose a citation manager

Content to export